Acadia Pharma press release (NASDAQ:ACAD): Q4 GAAP EPS of $0.86 beats by $0.63. Revenue of
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after
akinbostanci/iStock via Getty Images Acadia Pharmaceuticals (NASDAQ:ACAD) said that it expects to bring in product
Monty Rakusen On the final trading day of 2024, US stock futures were mainly lower
Acadia Pharmaceuticals (NASDAQ:ACAD) will replace Independent Bank Group (NASDAQ:IBTX) in the S&P SmallCap 600 effective
Grandbrothers Acadia Pharmaceuticals (NASDAQ:ACAD) said it has closed on the sale of its FDA Rare
Summary: NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is
designer491/iStock via Getty Images Acadia Pharmaceuticals (NASDAQ:ACAD) has entered into an exclusive global licensing deal
Summary: Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some
Acadia Pharma press release (NASDAQ:ACAD): Q3 GAAP EPS of $0.20 beats by $0.06. Revenue of